Biopharmaceutical Research Company (BRC) is in the permitting process with the Drug Enforcement Administration (DEA) and the Food and Drug Administration (FDA) to grow pharmaceutical grade cannabis for research purposes.
In accordance with federal law and the Code of Federal Regulations, BRC will only sell to DEA approved Schedule One Registrants after a rigorous diligence process.
BRC was founded to address the scarcity of high quality cannabis available for scientific research in America. Researchers are currently unable to legally source diverse cannabinoid profiles from a source that can assure uncontaminated products.
We take our responsibility to provide the scientific community with superior quality cannabis very seriously.